AlphAIAlphAI — Financial news for AI agents
3dprint.comSEP 82 min read

Quantum Cyber Completes Installation of 80 3D Printers at Connecticut Drone Farm - 3DPrint.com

Quantum Cyber, formerly Mainz Biomed, has installed 80 3D printers at a Connecticut facility to produce drones, aiming for 100,000 units annually. The company, taken over by activist investor David Lazar, licensed IP from BP United and plans various drone types, including interceptors. It also holds an equity stake in SpaceX.

Original reporting
3dprint.com
Published Sep 8, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Quantum Cyber Completes Installation of 80 3D Printers at Connecticut Drone Farm - 3DPrint.com — source image
Source · 3dprint.com
Decision brief

The 30-second read

Low
01

Why it matters

The installation of 80 printers signals operational progress but lacks clear revenue or contract details, limiting immediate price impact.

02

Market read

A niche micro‑cap story with modest relevance to defense and 3D‑printing sectors.

03

What to watch

Absence of disclosed contracts or funding sources raises questions about financial sustainability.

Relevance 5/10Novelty 6/10Timing: recently completed installation

Background

Quantum Cyber, formerly Mainz Biomed, has shifted from biotech to 3D‑printed drone manufacturing after an activist takeover.

Market effects

Sector

Potential boost to US defense drone sector if the company secures contracts.

Regional

May influence Connecticut manufacturing and local employment outlook.

Global

Limited; primarily a micro‑cap story with niche defense implications.

Counterpoint

What could challenge this read

The pivot could be a distraction; the company may lack the expertise to compete in defense drones.

Key entities

  • company
    Quantum Cyber

    Micro‑cap NASDAQ‑listed firm pivoting to drone production.

  • individual
    David Lazar

    Activist investor who led the takeover.

Read at source← All news

Related articles

JUL 16
$QUCYLow

Quantum Cyber N.V. (QUCY): Completion of Acquisition or Disposition of Assets

Quantum Cyber N.V. (QUCY) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001874252 00-0000000 0001874252 2026-07-15 2026-07-15 0001874252 dei:FormerAddressMember 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sect

SEC EDGAR 8-K3 min
MAY 28
$QUCYMedAI 8/10

Mainz Biomed NV (NASDAQ:QUCY) Short Interest Up 996.3% in May

Mainz Biomed NV (NASDAQ:QUCY) saw short interest rise sharply in May, reaching 10,530,990 shares as of May 15, up from 960,587 on April 30, according to the article. It says 79.6% of shares are sold short. The stock traded at $2.93, and the article cites mixed analyst ratings, with a consensus “Reduce” rating.

dailypolitical.com4 min
SEP 17
$METAMed

Meta Just Launched a New Subscription Business Built Entirely Around AI. Here's Why It Could Be a Game-Changer.

Meta Platforms (META) launched Meta One, a subscription service offering expanded AI features across Facebook, Instagram, and WhatsApp. Plans range from $7.99 to $499 per month. The move aims to diversify revenue as Meta faces high AI infrastructure costs and relies heavily on advertising. Meta's Q2 revenue rose 28% to $60.8B, but net income fell 15%. Analysts expect Q3 revenue of $73.66B.

fool.com3 min
SEP 17
$BIIBMedAI 8/10

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M

Biogen Inc. (BIIB) reported that EMPAVELI (pegcetacoplan) showed a 75% relative reduction in proteinuria in adolescents with C3G or primary IC-MPGN in a Phase 3 study. The FDA recently expanded EMPAVELI's label to include reducing kidney function loss in patients aged 12 and older. The drug is the only approved treatment for these conditions in adolescents, according to the company.

leaderpost.com2 min
SEP 17
$ABBVMed

Atogepant associated with reduced menstrual migraine days

AbbVie's atogepant (Qulipta) showed significant reductions in menstrual migraine days in a Phase 3 study. Patients saw a 1.2-day reduction vs. 0.4 days for placebo. The study met all secondary endpoints, including headache days and functional disability. AbbVie plans to assess long-term effects in an extension study. No new safety concerns were reported.

healio.com2 min
SEP 17
$BAMedAI 8/10

Examining Why Boeing's 777X Certification Timeline Is Likely Slipping

Boeing's CEO Kelly Ortberg stated that 777X certification testing will likely extend into 2027 due to unresolved engine mid-seal issues, delaying ETOPS authorization. GE Aerospace is working on a fix, with both companies planning 2027 deliveries. Labor negotiations also pose a risk to certification timelines. The 777X is seven years behind schedule, with airlines like Emirates and Lufthansa awaiting ETOPS for long-haul routes.

leehamnews.com3 min